Ozempic and Wegovy use semaglutide at higher doses designed for diabetes management or weight loss. Microdosing uses the same active ingredient at much lower doses—often starting at half the standard starting dose or less. The goal shifts from weight loss to metabolic optimization and longevity support. Side effects are typically milder and the approach is gentler.

Research suggests GLP-1 activation may support multiple aspects of healthy aging. These include reduced chronic inflammation (a driver of many age-related diseases), improved cardiovascular health, better insulin sensitivity, and potential neuroprotective effects. Some studies indicate GLP-1 may support cellular health by reducing oxidative stress. While more research is ongoing, the metabolic benefits are well-documented.

Most patients notice subtle improvements within the first few weeks—steadier energy, better sleep, reduced cravings, and improved mental clarity. Over 2-3 months, metabolic markers like blood sugar and inflammatory markers may improve. This is not a weight loss protocol, so dramatic changes in body weight are not expected, though some patients experience mild changes as a secondary effect.

Side effects with microdosing are typically mild and less frequent than with full-dose therapy. Some patients experience slight nausea in the first week or two, usually resolving quickly. Injection site reactions (redness, mild swelling) may occur but are generally minor. Serious side effects are rare at these doses but should be reported to your provider.

Microdosing is designed for long-term use as part of an overall health optimization strategy. Unlike weight loss protocols with specific endpoints, longevity-focused therapy can be continued indefinitely with regular provider oversight. Your provider will monitor your response and adjust as needed.